Liver Tumors in Pediatrics

Benign Liver Tumors

Benign hepatic neoplasms in children are uncommon but encompass a range of vascular, mesenchymal, and epithelial lesions. Early recognition and accurate characterization—often via ultrasound, CT, or MRI—guide management, which ranges from observation to medical therapy or surgical resection.

Primary tumors of the liver are rare and represent 0.3%–4% of all pediatric solid tumors.

A. Infantile Hepatic Hemangioma (IHH)

1. Epidemiology

• Most common benign liver tumor in infants (>70%); prevalence 0.4%–7.3% in autopsy series.
• 85% present by 6 months of age; female:male ratio ~1.5–2:1.

2. Pathogenesis

• Clonal proliferation of fetal endothelial cells; VEGF and GLUT-1 expression mark infantile subtype
• VEGF (Vascular endothelial growth factor) serves as a central regulator of this pathway..
• Arteriovenous shunts in multifocal and diffuse forms contribute to high-output heart failure.

3. Clinical Presentation

• Often asymptomatic abdominal mass; incidental on ultrasound. α-fetoprotein [AFP] normal.
  
• Associated findings: multiple cutaneous hemangiomas (≥5), consumptive coagulopathy (Kasabach-Merritt), anemia, thrombocytopenia, and hypothyroidism via tumor expression of type III deiodinase activity (inactivates thyroid hormone)
  
• Severe diffuse disease: abdominal compartment syndrome, respiratory compromise, high-output cardiac failure.

4. Classification & Natural History

a. Focal IHH

• Single, well-defined GLUT-1–negative spherical tumor; stops growing after birth and involutes over 12–18 months.
• Rarely associated with skin hemangiomas, usually asymptomatic
  

b. Multifocal IHH

• Multiple discrete GLUT-1–positive nodules; often with cutaneous hemangiomas.
• AV shunts present
  
• Grow during first year of life and slowly involute by age 5 years.

c. Diffuse IHH

• Extensive replacement of hepatic tissue with hemangiomas; highest risk of cardiac failure, hypothyroidism, and abdominal compartment syndrome, compression of IVC, thrombosis, necrosis.

5. Diagnosis

• Ultrasound: well defined, hyperechoic lobulated mass; Doppler shows high flow
• Triple-phase CT: hypoanttenuating mass with peripheral pooling and central enhancement
• MRI: T2-bright lesions with progressive contrast enhancement
• Biopsy reserved for atypical lesions or uncertain diagnosis

6. Management

• Observation in asymptomatic, involuting lesions; serial ultrasound and laboratory monitoring (AFP, thyroid function, platelet count).
• First-line therapy for symptomatic lesions: Propranolol 1–3 mg/kg/day in divided doses (response in 80% within weeks).
• Alternative medical agents: corticosteroids (2–3 mg/kg/day), vincristine (0.05 mg/kg/week), or sirolimus in refractory cases.
• Interventional: arterial embolization for heart failure or rapid growth.
• Surgical: resection or liver transplant for life-threatening diffuse disease unresponsive to medical therapy.

B. Mesenchymal Hamartoma (MH)

1. Epidemiology & Pathogenesis

• Second most common benign liver lesion in children; ~6% of pediatric hepatic tumors; 85% diagnosed <2 years old; slight male predominance (3:2).
• Etiology unclear; thought to arise from developmental malformation of mesenchyme.

2. Clinical Presentation

• Abdominal distention, palpable mass, vomiting, anorexia, and possible respiratory distress from diaphragmatic elevation.
• Rare prenatal detection on ultrasound as multicystic mass.
• AFP may be mildly elevated.

3. Imaging

• Ultrasound: multilocular cystic lesion with septations; echogenic stroma if cysts small.
• CT/MRI: well-circumscribed multicystic mass, variably proteinaceous fluid, occasional calcifications.

4. Natural History

• Variable: some lesions enlarge rapidly in infancy, then stabilize or regress; small risk (<5%) of transformation to undifferentiated embryonal sarcoma.

5. Management

• Asymptomatic small lesions: observation with periodic imaging due to potential spontaneous regression.
• Symptomatic or enlarging masses: complete surgical excision, often by segmentectomy or lobectomy.
• Percutaneous cyst drainage for temporary relief, but high recurrence.
• Orthotopic liver transplantation reserved for unresectable or life-threatening cases.

C. Focal Nodular Hyperplasia (FNH)

1. Epidemiology & Pathogenesis

• Represents ~2% of pediatric liver tumors; more frequent in girls; mean age around 8–10 years.
• Benign hyperplastic response to arteriovenous malformation; central stellate scar is pathognomonic.

2. Clinical Presentation

• Often asymptomatic; incidental detection on exam or imaging.
• Occasional abdominal pain or fullness.
• Normal AFP and liver function tests.

3. Imaging

• Ultrasound: well-demarcated, isoechoic or slightly hyperechoic mass; central scar may be hypoechoic.
• CT: arterial enhancement with central scar; isoattenuating in portal and delayed phases.
• MRI: T2-hyperintense scar; strong arterial phase enhancement and isointense thereafter.

4. Management

• Conservative: observation with ultrasound every 6–12 months if asymptomatic and imaging classic.
• Surgical resection for symptomatic lesions, uncertain diagnosis, or rapid growth.

D. Hepatic Adenoma

1. Epidemiology & Risk Factors

• Rare in children; female predominance; associated with oral contraceptive use and glycogen storage disease (type I and III).
• Subtypes based on molecular profile: HNF1α-inactivated, inflammatory, β-catenin-activated, and unclassified.

2. Clinical Presentation

• Often incidental; may present with RUQ pain or palpable mass.
• Risk of hemorrhage or rupture in larger lesions (>5 cm).

3. Diagnosis

• CT/MRI: arterial phase hyperenhancement; washout in portal phase; absence of central scar distinguishes from FNH.
• MRI chemical-shift imaging identifies intracellular fat in HNF1α subtype.
• AFP usually normal; tissue biopsy if imaging inconclusive or suspicion of hepatocellular carcinoma (HCC).

4. Management

• Observe adenomas <5 cm and low-risk subtype off estrogen exposure; serial imaging.
• Surgical resection for lesions >5 cm, β-catenin subtype, symptomatic tumors, or hemorrhage.
• Radiofrequency ablation or laparoscopic resection as minimally invasive options.

E. Other Benign Liver Tumors

• Teratoma: Contains elements of all three germ layers; presents as cystic/solid mass. Management: complete surgical excision; prognosis excellent for mature teratomas.
• Inflammatory Myofibroblastic Tumor: Rare spindle-cell neoplasm with ALK rearrangements; may mimic malignancy. Presents with fever, pain, weight loss. Imaging: heterogeneous mass, sometimes calcified. Treatment: surgical resection; ALK inhibitors for unresectable cases.
• Angiomyolipoma: Composed of blood vessels, smooth muscle, fat; associated with tuberous sclerosis. Imaging: fat-containing lesion on CT/MRI. Asymptomatic lesions <5 cm observed; larger or symptomatic lesions resected.
• Biliary Cystadenoma: Multiloculated cystic neoplasm lined by mucinous epithelium; rare in children. Presents with abdominal pain or mass. Imaging: septated cysts with internal nodules. Treatment: complete surgical excision to prevent malignant transformation.

Summary Table

Conclusion

Benign liver tumors in children encompass a spectrum of lesions with distinct clinical and imaging features. Management ranges from watchful waiting to medical therapy and surgical intervention. Multidisciplinary coordination among pediatric hepatology, radiology, oncology, and surgery ensures optimal outcomes and minimizes complications.

Malignant Liver Tumors in Pediatrics

Malignant hepatic neoplasms in children are rare but represent significant challenges in diagnosis and management. The most common entities are hepatoblastoma and hepatocellular carcinoma, followed by a spectrum of less frequent sarcomas and germ cell tumors. Early detection, accurate staging by PRETEXT or TNM systems, and multidisciplinary treatment planning are essential to optimize outcomes.

A. Hepatoblastoma (HB)

1. Epidemiology

• Accounts for ~40% of pediatric liver tumors; incidence 1.5–1.8 per million children.
• Peak presentation before age 3 years; male:female ratio 1.4–2.0:1.
• Rising incidence correlates with improved survival of very low birth weight and premature infants.

2. Histologic Subtypes

• Embryonal (most common), fetal, mixed epithelial, small cell undifferentiated, teratoid, rhabdoid.
• Pure fetal histology has excellent prognosis; small cell undifferentiated portends poor outcome.

3. Risk Factors

• Genetic syndromes: Beckwith–Wiedemann, familial adenomatous polyposis.
• Metabolic disorders: tyrosinemia, glycogen storage disease.
• Low birth weight (<1,000 g) and prematurity.
• Environmental exposures: parental occupational chemicals, maternal smoking.

4. Clinical Presentation

• Often an asymptomatic, firm, irregular right upper quadrant mass.
• Systemic signs: weight loss, anorexia, abdominal pain, vomiting; jaundice is rare.

5. Laboratory Findings

• Alpha-fetoprotein (AFP) elevated in ~90% of cases—interpret in context of age
  • Normal AFP at birth: 25,000–100,000 ng/mL; by 1 year: <10 ng/mL.
• Anemia (70%), thrombocytosis (35%).

6. Imaging

• Ultrasound: heterogeneous, circumscribed, lobulated lesions replacing liver parenchyma.
• CT: hypodense mass, often with calcifications; vascular supply from hepatic artery.
• MRI: better delineation of tumor extent and vascular invasion.

7. Staging (PRETEXT)

The PRETEXT system divides the liver into four sectors (left lateral, left medial, right anterior, right posterior) and assigns:

• I: one sector involved, three contiguous sectors tumor-free.
• II: one or two sectors involved, two contiguous sectors tumor-free.
• III: three sectors involved, one sector tumor-free.
• IV: all four sectors involved.

8. Diagnosis

Core needle biopsy confirms histology; careful technique minimizes risk of tumor seeding.

9. Management

• PRETEXT I/II: Upfront complete surgical resection followed by adjuvant chemotherapy (e.g., cisplatin-based per SIOPEL/COG protocols).
• PRETEXT III/IV: Neoadjuvant chemotherapy to shrink tumor, then delayed resection.
• Liver transplantation: Indicated for unresectable multifocal PRETEXT IV or localized PRETEXT II/III without metastases after chemotherapy response (decreased tumor size and AFP).
• Contraindications to transplant: persistent extrahepatic disease despite therapy.

10. Prognosis

Five-year survival exceeds 80% for standard-risk HB. Adverse prognostic factors include small cell undifferentiated histology, metastases at diagnosis, vascular invasion, and lack of AFP decline with therapy.

B. Hepatocellular Carcinoma (HCC)

1. Epidemiology

• Second most common pediatric liver malignancy; incidence 0.41 per million children.
• Male predominance; typically presents in adolescence.

2. Etiology & Risk Factors

• De novo tumors (60–70%) in normal liver.
• Chronic liver disease: HBV, HCV, tyrosinemia, biliary atresia, Fanconi anemia.
• Exogenous factors: anabolic steroids, oral contraceptives, methotrexate.

3. Clinical Presentation & Laboratory Findings

• Abdominal distention, hepatomegaly, weight loss, weakness, right upper quadrant pain.
• AFP elevated in 60–80%—helps distinguish from benign lesions.
• Occasionally paraneoplastic hormone production leads to precocious puberty.

4. Imaging

• Ultrasound: large, heterogeneous mass, often with vascular invasion.
• CT/MRI: arterial-phase hyperenhancement with rapid washout on portal/delayed phases.
  • Fibrolamellar variant: central scar and calcifications in adolescents with better prognosis.

5. Diagnosis & Staging

Imaging criteria often suffice; biopsy if uncertain. PRETEXT staging applies; TNM staging also used.

6. Management

• Complete surgical resection for solitary, resectable tumors.
• Liver transplantation for unresectable HCC without extrahepatic spread.
• Transarterial chemoembolization (TACE) or radiofrequency ablation for unresectable lesions as bridge to transplant.
• Systemic therapy with sorafenib or other kinase inhibitors is under investigation in pediatric cohorts.

7. Prognosis

Overall 5-year survival ranges 20–50% depending on stage, liver function, and resectability. Fibrolamellar carcinoma has a 50–75% 5-year survival after resection.

C. Other Malignant Liver Tumors

• Undifferentiated embryonal sarcoma of the liver—presents in older children; treated with resection and adjuvant chemotherapy.
• Rhabdoid tumor—aggressive, poor prognosis; SMARCB1‐deficient.
• Yolk sac tumor—germ cell origin; extremely elevated AFP; surgical and platinum-based chemotherapy.
• Rhabdomyosarcoma, leiomyosarcoma, and other sarcomas—rare; multimodal therapy.
• Nested stromal epithelial tumor—very rare epithelial–stromal neoplasm; surgical resection curative.
• Neuroblastoma stage IV-S—when metastases confined to liver, may spontaneously regress; supportive care often sufficient.

Summary Table

Conclusion

Pediatric malignant liver tumors require a tailored, multidisciplinary approach. Hepatoblastoma and hepatocellular carcinoma dominate the landscape, with PRETEXT staging guiding surgical timing and transplant candidacy. Rare sarcomas and germ cell tumors demand high index of suspicion and specialized protocols. Collaboration among pediatric oncology, hepatology, radiology, and transplant teams is essential to achieve the best outcomes.

References: